An Open-Label Study to Assess the Safety and Effect on Key Biomarkers of Oral RVX000222 in Subjects With Fabry Disease

Trial Profile

An Open-Label Study to Assess the Safety and Effect on Key Biomarkers of Oral RVX000222 in Subjects With Fabry Disease

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Jul 2017

At a glance

  • Drugs Apabetalone (Primary)
  • Indications Fabry's disease
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Sponsors Resverlogix Corporation
  • Most Recent Events

    • 20 Jul 2017 Status changed from planning to not yet recruiting.
    • 01 Jun 2017 New trial record
    • 30 May 2017 According to a Resverlogix Corporation media release, Dr. Michael West, Canadian Fabry Disease Initiative, Professor, Department of Medicine, Dalhousie University, Halifax NS will be the principal investigator of the study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top